Clinical trials · New York, NY
Metastatic Cancer clinical trials in New York
We’re tracking 313 recruiting metastatic cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
New York, New YorkAges 18 years+ - NCT06300463RecruitingPhase 2
Immunotherapy combinations for colorectal cancer with liver tumors
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
New York, New YorkAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
New York, New YorkAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
New York, New YorkAges 18 years+ - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
New York, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
New York, New YorkAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
New York, New YorkAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
New York, New YorkAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after abiraterone
This trial tests whether a drug called talazoparib, alone or combined with enzalutamide, can help people with a certain type of advanced prostate cancer that has stopped responding to abiraterone. It is for those who have a specific genetic change (HRR mutation) in their tumor.
New York, New YorkAges 18 years+ - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
New York, New YorkAges 18 years+ - NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
New York, New YorkAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
New York, New YorkAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
New York, New YorkAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
New York, New YorkAges 18 years+ - NCT07185997RecruitingPhase 3
Testing firmonertinib for a type of lung cancer with rare EGFR mutations
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
New York, New YorkAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT07111507RecruitingPhase 2
Tarlatamab for advanced prostate cancer
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
New York, New YorkAges 18 years+ - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
New York, New YorkAges 18 years+
Hear when a new Metastatic Cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Metastatic Cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting metastatic cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 12 studies
- NYU Langone Health · 9 studies
- Memorial Sloan Kettering Basking Ridge · 5 studies
- Memorial Sloan Kettering Bergen · 5 studies
- Memorial Sloan Kettering Commack · 5 studies
- Memorial Sloan Kettering Monmouth · 5 studies
- Memorial Sloan Kettering Nassau · 5 studies
- Rutgers Cancer Institute of New Jersey · 4 studies
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic cancer studies in New York.
Common questions
- Are there metastatic cancer clinical trials near New York?
- Yes. We're currently tracking 313 recruiting metastatic cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.